Lemtrada (alemtuzumab) / Bayer, Sanofi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lemtrada (alemtuzumab) / Sanofi
ACTRN12608000435381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study One

Active, not recruiting
3
581
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
ACTRN12608000426381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study Two

Active, not recruiting
3
700
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
2016-000464-42: The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab

Ongoing
3
100
Europe
Lemtrada, GZ402673, Concentrate for solution for infusion, Lemtrada
Genzyme GmbH, Genzyme GmbH
Relapsing-remitting multiple sclerosis, Relapsing-remitting multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
LemKids, NCT03368664 / 2016-003100-30: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Active, not recruiting
3
16
Europe, RoW
Alemtuzumab GZ402673, Lemtrada, Glatiramer acetate, Copaxone, Beta-Interferon, Methylprednisolone, Ranitidine, Ceterizine, Dexchlorpheniramine, Paracetamol, Acyclovir, Prednisolone, Diphenydramine, Other H1 antagonist
Genzyme, a Sanofi Company
Multiple Sclerosis
05/21
12/25
RAM-MS, NCT03477500 / 2017-001362-25: Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS

Recruiting
3
100
Europe
Cyclophosphamide and ATG, Sendoxan, Alemtuzumab, Lemtrada, Cladribine Pill, Mavenclad, Ocrelizumab, Ocrevus
Haukeland University Hospital
Multiple Sclerosis
03/24
03/26
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
ACTRN12621001502820p: Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial.

Not yet recruiting
2/3
80
 
Griffith University, Brazil Family Foundation
Multiple Sclerosis
 
 
ACTRN12621001502820: Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial.

Recruiting
2/3
80
 
Griffith University, Brazil Family Foundation
Multiple Sclerosis
 
 

Download Options